bioxcel therapeutics

BioXcel Therapeutics Announces Fourth Quarter and Fiscal Year 2019 Earnings

BioXcel Therapeutics Announces Fourth Quarter and Fiscal Year 2019 Earnings

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported fourth quarter and full year ended December 31st, 2019 financial results.  BXCL501 is designed for the treatment of acute agitation.  The company initiated phase 3 trials for acute tr..